Global Perspective Newsletter for December 2019

10 December 2019 - The December 2019 edition of our Global Perspective Newsletter is now available. Read the latest news from ADI, our partners and member associations, including updates on the upcoming World Alzheimer's Month, World Alzheimer Report, and much more. [read more]

ADI and DAI invite you to a joint webinar on dementia and rights

11 December 2019 – ADI is happy to announce that we will be hosting a joint webinar, Dementia & rights; from principles to practice, with Dementia Alliance International (DAI) on 27 February 2020. [read more]

China approves first drug for mild to moderate Alzheimer's in 17 years

4 November 2019 – Chinese Pharmaceutical Company Green Valley announced over the weekend that their drug Oligomannate (GV-971) has been granted conditional approval by the National Medical Products Administration (NMPA) as a new drug for the treatment of “mild to moderate Alzheimer's disease and improving cognitive function”. [read more]

Biogen and Eisai announce plans to file for market approval of Alzheimer's drug

22 October 2019 – Biogen and Eisai today announced that they will file for market approval for the drug aducanumab, an investigational treatment for early Alzheimer’s disease, following new analysis showing reduced clinical decline in people with early Alzheimer’s disease. [read more]

Syndicate content